Transcenta Says Ozekibart Found to Benefit Patients With Colorectal Cancer

MT Newswires Live

May 21

Transcenta (HKG:6628) said updated data from the phase 1/2 study of ozekibart found the drug benefited patients with colorectal cancer and kept the disease at bay, according to a Thursday filing with the Hong Kong bourse.

The firm holds a license to develop and commercialize the drug in the greater China region.

Results published by the company's partner Inhibrx Biosciences showed the medicine had an objective response rate of 20% in patients who had been treated with other drugs previously.

The median progression-free survival among the 45 evaluable patients from the trial was 5.5 months, while the overall disease control rate stood at 87%.

Inhibrx plans to meet with the U.S. Food and Drug Administration in the second half of 2026 to discuss further trials of ozekibart in colorectal cancer.

Meanwhile, Inhibrx submitted a biologics license application with the U.S. Food and Drug Administration seeking approval for ozekibart in conventional chondrosarcoma, a type of bone cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/news/2637080383"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2637080383\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2637080383?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637080383","market":"hk","top_or_hot":-1,"title":"Transcenta Says Ozekibart Found to Benefit Patients With Colorectal Cancer","media":"MT Newswires Live","content":"<html><body><p> Transcenta (HKG:6628) said updated data from the phase 1/2 study of ozekibart found the drug benefited patients with colorectal cancer and kept the disease at bay, according to a Thursday filing with the Hong Kong bourse.</p><p>The firm holds a license to develop and commercialize the drug in the greater China region.</p><p>Results published by the company's partner <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> showed the medicine had an objective response rate of 20% in patients who had been treated with other drugs previously.</p><p>The median progression-free survival among the 45 evaluable patients from the trial was 5.5 months, while the overall disease control rate stood at 87%.</p><p>Inhibrx plans to meet with the U.S. Food and Drug Administration in the second half of 2026 to discuss further trials of ozekibart in colorectal cancer.</p><p>Meanwhile, Inhibrx submitted a biologics license application with the U.S. Food and Drug Administration seeking approval for ozekibart in conventional chondrosarcoma, a type of bone cancer.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Transcenta Says Ozekibart Found to Benefit Patients With Colorectal Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTranscenta Says Ozekibart Found to Benefit Patients With Colorectal Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-21 10:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Transcenta (HKG:6628) said updated data from the phase 1/2 study of ozekibart found the drug benefited patients with colorectal cancer and kept the disease at bay, according to a Thursday filing with the Hong Kong bourse.</p><p>The firm holds a license to develop and commercialize the drug in the greater China region.</p><p>Results published by the company's partner <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> showed the medicine had an objective response rate of 20% in patients who had been treated with other drugs previously.</p><p>The median progression-free survival among the 45 evaluable patients from the trial was 5.5 months, while the overall disease control rate stood at 87%.</p><p>Inhibrx plans to meet with the U.S. Food and Drug Administration in the second half of 2026 to discuss further trials of ozekibart in colorectal cancer.</p><p>Meanwhile, Inhibrx submitted a biologics license application with the U.S. Food and Drug Administration seeking approval for ozekibart in conventional chondrosarcoma, a type of bone cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06628","symbol_name":"创胜集团医药-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2637080383","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637080383","pubTimestamp":1779330541,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Transcenta  said updated data from the phase 1/2 study of ozekibart found the drug benefited patients with colorectal cancer and kept the disease at bay, according to a Thursday filing with the Hong Kong bourse.The firm holds a license to develop and commercialize the drug in the greater China region.Results published by the company's partner Inhibrx Biosciences showed the medicine had an objective response rate of 20% in patients who had been treated with other drugs previously.The median progression-free survival among the 45 evaluable patients from the trial was 5.5 months, while the overall disease control rate stood at 87%.Inhibrx plans to meet with the U.S. Food and Drug Administration in the second half of 2026 to discuss further trials of ozekibart in colorectal cancer.Meanwhile, Inhibrx submitted a biologics license application with the U.S. Food and Drug Administration seeking approval for ozekibart in conventional chondrosarcoma, a type of bone cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06628":"创胜集团医药-B","BK1161":"生物科技"},"translate_title":"Transcenta称Ozekibart被发现有益于结直肠癌患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06628":1},"content_text":"Transcenta (HKG:6628) said updated data from the phase 1/2 study of ozekibart found the drug benefited patients with colorectal cancer and kept the disease at bay, according to a Thursday filing with the Hong Kong bourse.The firm holds a license to develop and commercialize the drug in the greater China region.Results published by the company's partner Inhibrx Biosciences showed the medicine had an objective response rate of 20% in patients who had been treated with other drugs previously.The median progression-free survival among the 45 evaluable patients from the trial was 5.5 months, while the overall disease control rate stood at 87%.Inhibrx plans to meet with the U.S. Food and Drug Administration in the second half of 2026 to discuss further trials of ozekibart in colorectal cancer.Meanwhile, Inhibrx submitted a biologics license application with the U.S. Food and Drug Administration seeking approval for ozekibart in conventional chondrosarcoma, a type of bone cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}